Neurocrine Biosciences

This study tests the long-term safety of an experimental drug called NBI-1117568 in 600 adults with schizophrenia. Participants must stop taking other antipsychotic medications before joining. The main goal is to track any side effects that occur during treatment.

This study tests whether valbenazine can reduce involuntary muscle movements in people with tardive dyskinesia who still have symptoms despite prior treatment. About 50 adults with schizophrenia, bipolar disorder, or major depression will take valbenazine for 24 weeks. The goal i…

This study tests whether the drug NBI-1117568 can delay or prevent the return of schizophrenia symptoms in adults who have already responded well to the drug. About 560 participants will first receive the drug openly, then be randomly assigned to continue the drug or switch to a …

This study tests whether an experimental drug called NBI-1065845 can help people with major depression stay well longer when added to their usual antidepressant. About 550 adults who haven't fully responded to current antidepressants will receive either the study drug or a placeb…

This study tests a drug called crinecerfont in 6 children under 2 years old who have congenital adrenal hyperplasia (CAH). The goal is to see how the drug moves through the body and if it is safe. All children will receive the drug, and researchers will monitor side effects and d…

This study tests the long-term safety of an experimental drug called NBI-1065845 when added to standard antidepressants for people with major depression. About 850 adults who haven't gotten enough relief from current treatments will take the drug for up to a year. The main goal i…

This study tests whether a new drug called NBI-1065845 can improve depression symptoms in adults who still feel depressed despite taking standard antidepressants. About 200 participants will receive either the study drug or a placebo pill alongside their usual medication for 8 we…

This study tests whether adding NBI-1065845 to standard antidepressants can better reduce depression symptoms in adults with major depressive disorder. About 200 participants who haven't fully responded to their current antidepressant will receive either the study drug or a place…

This study tests whether the experimental drug NBI-1117568 can reduce schizophrenia symptoms like hallucinations and delusions better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a placebo for 5 weeks while staying in the hospit…

This study tests a new drug called NBI-1117570 to see if it can improve schizophrenia symptoms like confusion, hallucinations, and mood changes. About 120 adults aged 18 to 55 who are currently hospitalized for a schizophrenia episode will receive either the drug or a placebo. Th…

This study tests whether adding NBI-1065845 to standard antidepressants can better relieve depression symptoms. About 200 adults with major depression who haven't fully responded to current meds will receive either the study drug or a placebo for 8 weeks. The main goal is to see …

This study tests a new medicine called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take part. The main goal is to measure changes in symptoms like hallucinations and delusions a…

This study tests an experimental drug, NBI-1065890, to see if it can reduce the involuntary movements caused by tardive dyskinesia. About 100 adults with conditions like schizophrenia or bipolar disorder who also have moderate to severe tardive dyskinesia will receive either the …

This study tests an experimental drug, NBI-1117568, to see if it can reduce manic symptoms in adults with bipolar I disorder who are hospitalized for a manic episode. About 150 participants will receive either the drug or a placebo, and doctors will measure changes in mania score…